Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | KLK1 | P06870 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25910329 | 0.90 | LMNA (0.65) | KLKB1LMNAHPGDKLK1SMN1; SMN2 | |
| SCHEMBL1981938 | 0.88 | KLKB1 (1.00) | KLKB1KLK1 | |
| Hydrochloric Acid SCHEMBL1985633 | 0.87 | KLKB1 (0.98) | KLKB1KLK1 | |
| Acetic Acid SCHEMBL29253774 | 0.85 | KLKB1 (0.94) | KLKB1KLK1 | |
| SCHEMBL30739265 | 0.85 | KLKB1 (0.71) | KLKB1LMNAHPGDKLK1 | |
| SCHEMBL30739101 | 0.84 | KLKB1 (0.83) | KLKB1KLK1 | |
| SCHEMBL30739095 | 0.83 | KLKB1 (0.82) | KLKB1KLK1 | |
| SCHEMBL2858761 | 0.82 | LMNA (0.76) | KLKB1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL16365808 | 0.82 | KLKB1 (0.80) | KLKB1KLK1 | |
| SCHEMBL30739034 | 0.82 | KLKB1 (0.84) | KLKB1KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234927-A1 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | REZOLUTE INC (US) | 2023-07-27 | — | — | US | disclosed |
| US-11267790-B2 | Processes for preparing plasma kallikrein inhibitors | REZOLUTE, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021217053-A1 | PLASMA KALLIKREIN INHIBITORS FOR THE TREATMENT OF ARDS AND RELATED CONDITIONS | REZOLUTE, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210009526-A1 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | REZOLUTE, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2021007190-A1 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | REZOLUTE, INC. (US) | 2021-01-14 | — | — | WO | disclosed |
| US-20140348850-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | JOSLIN DIABETES CENTER | 2014-11-27 | — | — | US | disclosed |
| US-8658685-B2 | Methods for treatment of kallikrein-related disorders | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2051707-B1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-2051707-B1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8258170-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | Activesite Phamaceuticals, Inc. (US) | 2011-12-08 | — | — | US | disclosed |
| US-7977380-B2 | Inhibitors of plasma kallikrein | Activesite Pharmaceticals, Inc. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977380-B2 | Inhibitors of plasma kallikrein | Activesite Pharmaceticals, Inc. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | JOSKIN DIABETES CENTER (US) | 2011-03-17 | — | — | US | disclosed |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
| US-7625944-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625944-B2 | Inhibitors of plasma kallikrein | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | ACTIVESITE PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009526-A1 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | C1R, C1S, KLKB1 | KLKB1 3/4885LMNA 2269/4885HPGD 1774/4885 |
| US-20110065757-A1 | METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS | KLKB1, SERPINE1, KLK1 | KLKB1 1/4885LMNA 1203/4885HPGD 733/4885 |
| US-20080038276-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | KLKB1 1/4885LMNA 793/4885HPGD 456/4885 |
| US-20100130563-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | KLKB1 1/4885LMNA 793/4885HPGD 456/4885 |
| US-20140348850-A1 | METHOD FOR REDUCING BLOOD PRESSURE USING INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK2 | KLKB1 1/4885LMNA 1481/4885HPGD 347/4885 |
| US-11267790-B2 | Processes for preparing plasma kallikrein inhibitors | C1R, C1S, KLKB1 | KLKB1 3/4885LMNA 2269/4885HPGD 1774/4885 |
| US-20230234927-A1 | PROCESSES FOR PREPARING PLASMA KALLIKREIN INHIBITORS | C1R, C1S, KLKB1 | KLKB1 3/4885LMNA 1998/4885HPGD 1697/4885 |
| US-20110301215-A1 | INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK5 | KLKB1 1/4885LMNA 793/4885HPGD 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.